Jump to content

PubMed RSS Feed - -Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: a retrospective case-series


Recommended Posts

Dermatol Ther. 2022 Sep 29:e15848. doi: 10.1111/dth.15848. Online ahead of print.


Rosacea is a chronic inflammatory skin disease characterized by facial erythema, papules, pustules, telangiectasia and flushing. The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway appears to play a role in the pathogenesis of rosacea. Our study preliminarily explored the efficacy of JAK inhibitor tofacitinib in the treatment of rosacea. We retrospectively reviewed the cases of 21 patients with rosacea who were treated with oral tofacitinib. Patients received oral tofacitinib 5 mg as either monotherapy or adjunctive therapy. We have observed that 15 out of 21 patients (71.4%) patients experienced significant regression of erythema on the face (IGA≤1), and a mean change of -2.24 in the Investigator's Global Assessment (IGA) score was significant improvement from baseline. Treatment with oral tofacitinib might be a potentially effective treatment to ameliorate the symptoms of rosacea.

PMID:36175135 | DOI:10.1111/dth.15848

{url} = URL to article

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...

Important Information

Terms of Use